Cytokinetics, Inc. Announces Seven Posters To Be Presented At The 45th Annual American Society Of Cell Biology Meeting

SOUTH SAN FRANCISCO, Calif., Dec. 7 /PRNewswire-FirstCall/ -- Cytokinetics, Inc. announced today that seven posters relating to its research programs will be presented at the 45th Annual American Society of Cell Biology (ASCB) meeting at Moscone Convention Center (Halls A,B,C) in San Francisco, CA. Details regarding the scientific presentations are provided below:

Sunday, December 11, 12:00 pm - 3:00 pm

1. Abstract #653: A Comparison of Two High-Throughput Assays for FtsZ Inhibitors (Session #140, Parasitology)

Monday, December 12, 12:00 pm - 3:00 pm

1. Abstract #925: Identification and Biochemical Characterization of Small Molecule Arp2/3 Complex Inhibitors (Session # 216, Actin Dynamics & Assembly I)

Tuesday, December 13, 12:00 pm - 3:00 pm

1. Abstract #1728: In Vitro and In Vivo Efficacy of the Cardiac Myosin Activator CK-1827452 (Session #318, Muscle: Biochemistry & Cell Biology I)

2. Abstract #1729: A Multiplexed and Automated Imaging Assay of Cardiac Myocyte Contractility (Session #318, Muscle: Biochemistry & Cell Biology I)

3. Abstract #1747: Chemical and Genetic Disruption of Candida Albicans Kip1p: A Unique Bipolar Kinesin (Session #319, Kinesin I)

4. Abstract #1754: Microtubule Depolymerization Activity of a Kip3 Kinesin: Results from a Novel High-throughput Microtubule Depolymerization Assay (Session #320, Microtubule Dynamics & Assembly II)

Wednesday, December 14, 12:00 pm - 3:00 pm

1. Abstract #2463: Image-Based Identification of Small-Molecule Inhibitors of Yeast Pathogen Morphogenesis (Session #419, Cytoskeletal Organization II)

About Cytokinetics

Cytokinetics is a leading biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that specifically target the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Cytokinetics’ focus on the cytoskeleton enables it to develop novel and potentially safer and more effective classes of drugs directed at treatments for cancer, cardiovascular disease and other diseases. Cytokinetics has developed a cell biology driven approach and proprietary technologies to evaluate the function of many interacting proteins in the complex environment of the intact human cell. Cytokinetics employs the PUMA(TM) system and Cytometrix(TM) technologies to enable early identification and automated prioritization of compounds that are highly selective for their intended protein targets without other cellular effects, and may therefore be less likely to give rise to clinical side effects. Cytokinetics and GlaxoSmithKline have entered into a strategic alliance to discover, develop and commercialize small molecule therapeutics targeting human mitotic kinesins for applications in the treatment of cancer and other diseases. GlaxoSmithKline is conducting Phase II and Phase Ib clinical trials for ispinesib (SB-715992) and a Phase I clinical trial for SB-743921, each a drug candidate that has emerged from the strategic alliance. Cytokinetics’ heart failure program is the second program to leverage the company’s expertise in cytoskeletal pharmacology. Cytokinetics recently initiated a Phase I human clinical trial with CK-1827452, a novel small molecule cardiac myosin activator, for the treatment of heart failure. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements relating to the potential benefits of our drug candidates and potential drug candidates and the enabling capabilities of our proprietary technologies. Such statements are based on management’s current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of Cytokinetics’ drug candidates that could slow or prevent clinical development or product approval (including the risks relating to uncertainty of patent protection for Cytokinetics’ intellectual property or trade secrets, Cytokinetics’ ability to obtain additional financing if necessary and unanticipated research and development and other costs). For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission.

Cytokinetics, Inc.

CONTACT: Robert I. Blum, EVP, Corporate Development and CommercialOperations, and CBO of Cytokinetics, Inc., +1-650-624-3000; or investors,Clay A. Kramer, or media, Justin Jackson +1-212-213-0006, both of BurnsMcClellan, Inc., for Cytokinetics, Inc.

MORE ON THIS TOPIC